Reduction and residual proteinuria are therapeutic targets in type 2 diabetes with overt nephropathy: a post hoc analysis (ORIENT-proteinuria)

Proteinuria as a surrogate end point—more data are needed

(2012) Aliza Thompson   Nature Reviews Nephrology

Proteinuria should be used as a surrogate in CKD

(2012) Paolo Cravedi et al.   Nature Reviews Nephrology

Initial Angiotensin Receptor Blockade-Induced Decrease in Albuminuria Is Associated With Long-Term Renal Outcome in Type 2 Diabetic Patients With Microalbuminuria: A post hoc analysis of the IRMA-2 trial

(2011) M. E. Hellemons et al.   DIABETES CARE

Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study

(2011) E. Imai et al.   DIABETOLOGIA

Changes in Albuminuria Predict Mortality and Morbidity in Patients with Vascular Disease

(2011) R. E. Schmieder et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts

(2011) Brad C. Astor et al.   KIDNEY INTERNATIONAL

Proteinuria as a Surrogate Outcome in CKD: Report of a Scientific Workshop Sponsored by the National Kidney Foundation and the US Food and Drug Administration

(2009) Andrew S. Levey et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

International Comparisons

(2008)   AMERICAN JOURNAL OF KIDNEY DISEASES